Volume 10 Supplement 1
Surgical treatment in critical limb ischaemia
© Roscitano and Cotroneo; licensee BioMed Central Ltd. 2010
Published: 19 May 2010
Recommendations of clinical guidelines for the treatment of critical limb ischemia (CLI) are based on randomized controlled trials . Surgery using different grafts (venous or prosthetic) is in competition with percutaneous angioplasty. Progress of endoluminal techniques has brought certain authors to think that angioplasty is now the first treatment of critical limb ischemia .
Materials and methods
The indications of TASC II are: endovascular for type A, endovascular (with qualifications) for type B, open surgical (with qualifications) for type C, and open surgical for type D. .
Our experience, from 2000 to 2009, is of 377 patients (250 m - 127 f.). We perform distal revascularizations (tibial, peroneal and plantar) with great, small saphen vein and veins of the arm on 407 limbs. Mean age: 72 y. (19-25). Our patients had as risk factors: IDDM 66%, CAD 47%, CABG 8%, COPD 70%, ESRD 20% and 9,5% were in dialytic treatment.
We have a 30 day mortality rate of 2.7%, graft occlusion 9% and amputation 2.6%. Comparing our results to those of the literature for venous or prosthetic bypasses and distal angioplasties, we remain convinced of the high efficiency, in the long run, of infra-popliteal venous bypass grafts. Meanwhile, recent data on distal angioplasties are promising and in constant progress. .
- Lawall H, et al: Long-term outcomes after medical and interventional therapy of critical limb ischemia. Eur J Intern Med. 2009, 20 (6): 616-21. 10.1016/j.ejim.2009.06.002.PubMedView ArticleGoogle Scholar
- De Vos B, et al: Do surgical distal bypasses still play a role in the treatment of critical limb ischemia?. Acta Chir Belg. 2009, 109 (4): 465-76.PubMedGoogle Scholar
- Lyden SP, Smouse HB: TASC II and the endovascular management of infrainguinal disease. J Endovasc Ther. 2009, 16 (2 Suppl 2): II5-18. 10.1583/08-2659.1.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd.